Postacute Sequelae Following Omicron COVID-19 in Patients With Cancer
JAMA Network Open 10.1001/jamanetworkopen.2026.4037March 31, 2026 at 11:00 AM EDT
What is the risk of postacute sequelae of SARS-CoV-2 infection (or long COVID) in patients with cancer who are vaccinated and/or boosted against COVID-19 and infected with SARS-CoV-2 during Omicron predominance?In a cohort of 76 807 patients with cancer, no significant elevation in overall risk of postacute sequelae compatible with long COVID was observed among those infected with the SARS-CoV-2 Omicron variant, compared with noninfected patients. However, patients with cancer who were hospitalized for COVID-19 had a 36% to 48% higher risk of postacute sequelae compared with noninfected patients.These findings suggest that emergence of a milder Omicron variant and widespread vaccination attenuated risk of long COVID among patients with cancer during endemicity, except for hospitalized patients with more severe COVID-19.
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Need more information? Contact us.